Inhibition of AKT in human pancreatic, renal and colorectal cancer cells by four cardiac hormones

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 785-790

  Skelton IV, William P ^a   Skelton, Michelle ^b   Vesely, David L ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

AKT; Cardiac hormones; Colorectal adenocarcinomas; Pancreatic carcinomas; Renal adenocarcinoma

Indexed keywords

ATRIAL NATRIURETIC FACTOR; HORMONE; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; PROTEIN KINASE B; UNCLASSIFIED DRUG; VESSEL DILATOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; KIDNEY CANCER; PANCREAS CANCER; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ATRIAL NATRIURETIC FACTOR; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84875904511     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase- AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
2. Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464, 2005.
3. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
4. Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183, 2005.
5. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 441: 424-430, 2006.
6. Crowell JA, Steele VE and Fay JR: Targeting the Akt protein kinase for cancer chemoprevention. Mol Cancer Ther 6: 2139-2148, 2007.
7. Staal SP, Hartley JW and Rowe WP: Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci USA 74: 3065-3067, 2007.
8. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT and Smyrk TC: AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23: 201-205, 2002.
9. Eichelbaum EJ, Sun Y, Alli AA, Gower WR Jr. and Vesely DL: Cardiac hormones and urodilatin eliminate up to 86% of human small-cell lung carcinomas in mice. Eur J Clin Invest 38: 562-570, 2008.
10. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL and Gower WR Jr.: Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 21: 445-452, 2007.
11. Vesely DL, Vesely BA, Eichelbaum EJ, Sun Y, Alli AA and Gower WR Jr.: Four cardiac hormones eliminate up to twothirds of human breast cancers in athymic mice. In Vivo 21: 973-978, 2007.
12. Gower WR Jr., Vesely BA, Alli AA and Vesely DL: Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3',5'-cyclic monophosphate. Int J Gastrointestinal Cancer 36: 77-87, 2005.
13. Sun Y, Eichelbaum EJ, Skelton WP IV, Lenz A, Regales N, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 29: 971-975, 2009.
14. Sun Y, Eichelbaum EJ, Lenz A, Skelton WP IV, Wang H and Vesely DL: Atrial natriuretic peptide and long-acting natriuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 29: 1889-1893, 2009.
15. SunY, Eichelbaum EJ, Lenz A, Wang H and Vesely DL: Epidermal growth factor's activation of Ras is inhibited by four cardiac hormones. Eur J Clin Invest 40: 408-413, 2010.
16. Zhang X, Gaspard JP and Chung DC: Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 61: 6050-6054, 2001.
17. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 295: 1182-1186, 1971.
18. Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocrine Reviews 25: 581-611, 2004.
19. Hoeben A, Landuyt B, Highley MS, Wilders H, Van Oosterom AT and DeBruijin EA: Vascular endothelial growth factor. Pharmacol Rev 56: 549-580, 2004.
20. McMahon G: VEGF receptor signaling in tumor angiogenesis. Oncologist 5(Suppl 1): S3-S10, 2000.
21. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V and Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phospatidylinositol 3'- kinase/Akt signal transduction pathway: requirement for Flk- 1/KDR activation. J Biol Chem 273: 30336-30343, 1998.
22. Fujio Y and Walsh K: Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchoragedependent manner. J Biol Chem 274: 16349-16354, 1999.
23. Doanes AM, Hegland DD, Sethi R, Kovesdi I, Bruder JT and Finkel T: VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem Biophys Res Commun 255: 545-548, 1999.
24. Meadows KN, Bryant P and Pumiglia K: Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 276: 49289-49298, 2001.
25. Okada F, Rak JW, St Croix B, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T and Kerbel RS: Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 95: 3609-3614, 1998.
26. Nguyen JP, Frost CD, Lane ML, Skelton WP IV, Skelton M and Vesely DL: Novel dual inhibitors of vascular endothelial growth factor and the VEGFR2 receptor. Eur J Clin Invest 42: 1061-1067, 2012.
27. Serafino A, Moroni N, Psaila R, Zonfrillo M, Andreola F, Wannenes F, Mercuri L, Rasi G and Pierimarchi P: Antiproliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between acidic tumor microenvironment and Wnt/beta-catenin signaling. Biochim Biophys Acta 1822: 1004-1018, 2012.
28. Fukumoto S, Hsieh C-M, Maemura K, Layne MD, Yet S-F, Lee K-H, Matsui T, Rosenzweig A, Taylor WG, Rubin JS, Perrella MA and Lee ME: Akt participation in the Wnt signaling pathway through dishevelled. J Biol Chem 276: 17479-17483, 2001.
29. Li J, Mizukiami Y, Zhang X, Jo W-S and Chung DC: Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology 128: 1907-1918, 2005.
30. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M and Aozasa K: Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 10: 2846-2850, 2004.
31. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, Giovannucci E, Fuchs CS and Ogino S: Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 117: 1398-1408, 2011.
32. Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, Danilin S, Rothhut S, Jacqmin D, Helwig JJ and Massfelder T: The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 66: 5130-5142, 2006.